Literature DB >> 27893717

Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.

J Feng1, L Li1,2, N Zhang3, J Liu1, L Zhang4, H Gao4, G Wang5, Y Li5, Y Zhang1, X Li3, D Liu6, J Lu3, B Huang1.   

Abstract

The role of androgen and androgen receptor (AR) in breast carcinogenesis has long been a disputed issue. This report provides a mechanistic insight into how androgen and AR contributes to invasion and metastasis of breast cancer. We find that dihydrotestosterone (DHT) is able to induce the epithelial-to-mesenchymal transition in breast cancer cells in an AR-dependent/estrogen receptor-independent manner. This process is dependent on the demethylation activity of lysine-specific demethylase 1A (LSD1) by epigenetically regulating the target genes E-cadherin and vimentin. In vivo, DHT promotes metastasis in a nude mouse model, and AR and LSD1 are indispensable in this process. We establish that higher expression of nucleus AR to cytoplasm AR associated with worse prognostic outcomes in breast cancer patient samples. This study maps an 'androgen-AR/LSD1-target genes' pathway in breast carcinogenesis, implicating the importance of hormonal balance in women, and the potential clinical significance of serum androgen and AR in prediction of breast cancer and selection of breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27893717     DOI: 10.1038/onc.2016.432

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  85 in total

1.  Expression and clinical significance of androgen receptor in triple negative breast cancer.

Authors:  Xiang Luo; Yan-Xia Shi; Zhi-Ming Li; Wen-Qi Jiang
Journal:  Chin J Cancer       Date:  2010-06

2.  Plasma sex steroid hormones and breast cancer risk in Chinese women.

Authors:  Herbert Yu; Xiao-Ou Shu; Runhua Shi; Qi Dai; Fan Jin; Yu-Tang Gao; Benjamin D L Li; Wei Zheng
Journal:  Int J Cancer       Date:  2003-05-20       Impact factor: 7.396

3.  Expression of androgen receptor in breast cancer and its significance as a prognostic factor.

Authors:  Q Yu; Y Niu; N Liu; J Z Zhang; T J Liu; R J Zhang; S L Wang; X M Ding; X Q Xiao
Journal:  Ann Oncol       Date:  2010-11-25       Impact factor: 32.976

4.  Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.

Authors:  Isabella Castellano; Elena Allia; Valeria Accortanzo; Anna Maria Vandone; Luigi Chiusa; Riccardo Arisio; Antonio Durando; Michela Donadio; Gianni Bussolati; Alan S Coates; Giuseppe Viale; Anna Sapino
Journal:  Breast Cancer Res Treat       Date:  2010-02-03       Impact factor: 4.872

5.  Serum testosterone levels and breast cancer recurrence.

Authors:  Franco Berrino; Patrizia Pasanisi; Cristina Bellati; Elisabetta Venturelli; Vittorio Krogh; Antonio Mastroianni; Edoardo Berselli; Paola Muti; Giorgio Secreto
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

Review 6.  The histone LSD1 demethylase in stemness and cancer transcription programs.

Authors:  Stefano Amente; Luigi Lania; Barbara Majello
Journal:  Biochim Biophys Acta       Date:  2013-05-16

7.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Authors:  Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

Review 8.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Authors:  Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2013-11-22       Impact factor: 13.506

9.  Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.

Authors:  Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

10.  Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study.

Authors:  A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  32 in total

1.  Interrelation of androgen receptor and miR-30a and miR-30a function in ER-, PR-, AR+ MDA-MB-453 breast cancer cells.

Authors:  Shuhua Lyu; Han Liu; Xia Liu; Shan Liu; Yahong Wang; Qi Yu; Yun Niu
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

2.  The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.

Authors:  Elizabeth A Wellberg; L Allyson Checkley; Erin D Giles; Stevi J Johnson; Robera Oljira; Reema Wahdan-Alaswad; Rebecca M Foright; Greg Dooley; Susan M Edgerton; Sonali Jindal; Ginger C Johnson; Jennifer K Richer; Peter Kabos; Ann D Thor; Pepper Schedin; Paul S MacLean; Steven M Anderson
Journal:  Horm Cancer       Date:  2017-07-24       Impact factor: 3.869

Review 3.  Body composition and breast cancer risk and treatment: mechanisms and impact.

Authors:  Toshiaki Iwase; Xiaoping Wang; Tushaar Vishal Shrimanker; Mikhail G Kolonin; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2021-01-21       Impact factor: 4.872

4.  Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors.

Authors:  Emily Smart; Svetlana E Semina; Luis H Alejo; Nidhi S Kansara; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

5.  Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Authors:  Valerie N Barton; Jessica L Christenson; Michael A Gordon; Lisa I Greene; Thomas J Rogers; Kiel Butterfield; Beatrice Babbs; Nicole S Spoelstra; Nicholas C D'Amato; Anthony Elias; Jennifer K Richer
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 6.  Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.

Authors:  Jessica L Christenson; Jane B Trepel; Haythem Y Ali; Sunmin Lee; Joel R Eisner; Edwina S Baskin-Bey; Anthony D Elias; Jennifer K Richer
Journal:  Horm Cancer       Date:  2018-01-16       Impact factor: 3.869

7.  Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS.

Authors:  Lingxia Liu; Xiliu Zhang; Huayi Ding; Xin Liu; Donghui Cao; Yingqi Liu; Jiwei Liu; Cong Lin; Na Zhang; Guannan Wang; Jingyao Hou; Baiqu Huang; Yu Zhang; Jun Lu
Journal:  Oncogene       Date:  2021-04-29       Impact factor: 9.867

8.  Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer.

Authors:  Jiwei Liu; Jingxin Feng; Lili Li; Luyao Lin; Jiafei Ji; Cong Lin; Lingxia Liu; Na Zhang; Dandan Duan; Zhongwei Li; Baiqu Huang; Yu Zhang; Jun Lu
Journal:  EMBO Rep       Date:  2019-12-12       Impact factor: 8.807

Review 9.  Triple-negative breast cancer: new treatment strategies in the era of precision medicine.

Authors:  Song-Yang Wu; Hai Wang; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Sci China Life Sci       Date:  2020-08-11       Impact factor: 6.038

10.  Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.

Authors:  Savitha Rajarajan; Aruna Korlimarla; Annie Alexander; C E Anupama; Rakesh Ramesh; B S Srinath; T S Sridhar; Jyothi S Prabhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.